SPG 4 Denovo

How Rare Disease Families Need to Start Rethinking How Cures Get Built

For a long time, rare disease advocacy has followed a simple instinct: focus on your own disease, fund your own research, hope your cure comes next. It’s understandable. When it’s your child, your diagnosis, your future on the line, narrowing the focus feels like survival.

But here’s the uncomfortable truth:

That approach is slowing progress.

Not because families aren’t committed — they are. Not because researchers don’t care — they do. The problem is structural. Drug development, especially gene therapy and neurologic disease research, doesn’t scale well when every ultra-rare condition tries to solve the problem independently.

And increasingly, science doesn’t work that way anyway.

Cures Aren’t Built Disease-by-Disease Anymore

Modern therapeutics — gene therapy, RNA modulation, genome editing, delivery vectors — are platforms.

The same viral delivery system that helps one neurologic condition today may help ten tomorrow. Manufacturing pipelines, safety data, dosing strategies, and regulatory experience all accumulate across diseases.

When advocacy fragments funding and attention into tiny silos, progress slows for everyone.

Collaboration isn’t charity.

It’s acceleration.

The Cost Reality Nobody Likes Talking About

Getting a therapy from concept to early human trials can cost tens of millions of dollars — sometimes far more. Manufacturing clinical-grade gene therapy vectors alone can consume a large chunk of a small foundation’s resources.

For ultra-rare diseases, that financial reality means:

Single-disease funding often isn’t enough

Academic labs struggle to bridge the translational gap

Promising science stalls before patients ever see it

This isn’t pessimism. It’s math.

Families deserve honesty about that.

The Strategic Shift Rare Disease Advocacy Needs

Instead of asking only:

“How do we cure our disease?”

More families are starting to ask:

“How do we build the platforms that make many cures possible?”

That means:

Supporting shared delivery technologies

Collaborating across related neurologic conditions

Investing upstream, not just downstream

Encouraging data sharing and coordinated trials

It’s less emotionally satisfying than a disease-specific headline.

But it’s far more likely to produce real therapies.

This Isn’t Betrayal of Your Own Community

Some families worry that broad collaboration dilutes focus.

In reality, the opposite is true.

When progress happens anywhere in a related field:

Safety data accumulates

Manufacturing becomes cheaper

Regulators gain confidence

Researchers move faster

Helping another condition today may directly help your child tomorrow.

That’s not betrayal.

That’s strategy.

That’s Grace.

What Families Can Do Right Now

You don’t have to run a lab or fund a clinical trial to shift the landscape. You can:

Advocate for cross-disease research funding

Support platform technologies, not just disease-specific projects

Share your story in ways that highlight broader scientific needs

Encourage collaboration rather than competition among advocacy groups

Small shifts in messaging ripple outward.

The Bottom Line

Rare disease families are some of the strongest advocates in medicine. But strength alone isn’t enough — strategy matters.

The future of cures will be built on shared science, shared platforms, and shared momentum. The sooner advocacy reflects that reality, the sooner therapies move from possibility to practice.

And for families waiting on answers, time is the one resource none of us can afford to waste.